whatshot

DNTH   $28.97  3.35% Market Closed After Close 29.5 1.83%

Dianthus Therapeutics Inc
show_chart Advanced Chart of DNTH

Current temperature: 8.02
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 10
Target Price Mean 50
Mean unverified/preliminary 50 / 50
Target Price Low / High 36 / 84
Median / STD DEV 47 / 13.36
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Sell
rsi Sell ActivelyBuy Sell
macd Sell None None
stoch Sell None None
ma20 Sell Sell None
ma50 Sell None None
ma100 Sell Sell Sell
Candlestick PatternOct. 4, 2024 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US2528281080
ceo Mr. Marino Garcia M.B.A.
Website https://dianthustx.com
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.